Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Teva Pharmaceutical Industries ( TEVA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.1%. By the end of trading, Teva Pharmaceutical Industries rose $0.95 (2.1%) to $45.39 on average volume. Throughout the day, 8,560,097 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 5,939,400 shares. The stock ranged in a price between $44.12-$45.43 after having opened the day at $44.45 as compared to the previous trading day's close of $44.44. Other companies within the Drugs industry that increased today were: Pernix Therapeutics Holdings ( PTX), up 68.9%, Pain Therapeutics ( PTIE), up 21.4%, Star Scientific ( STSI), up 20.9% and Usana Health ( USNA), up 17.4%.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $37.2 billion and is part of the health care sector. Shares are up 10.9% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Teva Pharmaceutical Industries a buy, 3 analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Conatus Pharmaceuticals ( CNAT), down 12.9%, Stemline Therapeutics ( STML), down 12.1%, Pacific Biosciences of California ( PACB), down 11.5% and PDL BioPharma ( PDLI), down 11.0% , were all laggards within the drugs industry with Regeneron Pharmaceuticals ( REGN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Micron Spikes After $10 Billion Buyback Plan Caps Bullish Q3 Earnings Forecast

Micron Spikes After $10 Billion Buyback Plan Caps Bullish Q3 Earnings Forecast

Oil Prices, China Tariffs, Micron and Kohl's - 5 Things You Must Know

Oil Prices, China Tariffs, Micron and Kohl's - 5 Things You Must Know

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

Global Stocks Push Higher as China Tariff Move, Softer US Dollar Boost Sentiment

Global Stocks Push Higher as China Tariff Move, Softer US Dollar Boost Sentiment